Eli Lilly and Company (LLY)vsOscar Health Inc (OSCR)
LLY
Eli Lilly and Company
$1,372.99
+6.63%
HEALTHCARE · Cap: $1.12T
OSCR
Oscar Health Inc
$30.48
-2.78%
HEALTHCARE · Cap: $9.84B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 420% more annual revenue ($79.67B vs $15.32B). LLY leads profitability with a 33.5% profit margin vs 3.6%. OSCR trades at a lower P/E of 24.7x. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
OSCR
Buy64
out of 100
Grade: C+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Revenue surging 70.4% year-over-year
Earnings expanding 125.6% YoY
Conservative balance sheet, low leverage
Generating 2.0B in free cash flow
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 36.1x book value
3.6% margin — thin
Weak financial health signals
ROE of -2.4% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : OSCR
The strongest argument for OSCR centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 70.4% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 42.2x leaves little room for execution misses. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : OSCR
The primary concerns for OSCR are Profit Margin, Piotroski F-Score, Return on Equity. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
LLY profiles as a growth stock while OSCR is a hypergrowth play — different risk/reward profiles.
OSCR carries more volatility with a beta of 2.47 — expect wider price swings.
OSCR is growing revenue faster at 70.4% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 64/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Oscar Health Inc
HEALTHCARE · HEALTHCARE PLANS · USA
Oscar Health, Inc. offers health insurance products and services to individuals, families, and businesses in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?